Advaxis, Inc. (OTCMKTS:ADXS – Get Rating)'s stock price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.00 and traded as high as $3.47. Advaxis shares last traded at $3.06, with a volume of 1,068 shares traded.
Wall Street Analysts Forecast Growth
Separately, StockNews.com started coverage on shares of Advaxis in a research report on Monday, August 22nd. They issued a "sell" rating on the stock.
Get Advaxis alerts:Advaxis Stock Up 0.3 %
The firm has a 50-day moving average of $3.57. The stock has a market capitalization of $5.56 million, a P/E ratio of -30.60 and a beta of 2.07.
About Advaxis
(Get Rating)Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.
Recommended Stories
- Get a free copy of the StockNews.com research report on Advaxis (ADXS)
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- This Is What To Expect From The Q3 Earnings Reporting Season
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.